Protocol Ledger

NCT03711929 · Phase III · TERMINATED

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Interventional Phase III clinical trial protocol NCT03711929 sponsored by Santen in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-11-19 Enrollment: 145 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03711929
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)145 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03711929
Protocol FieldVerified Registry Value
NCT IdentifierNCT03711929
Consolidated Lead SponsorSanten
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment145 participants (ACTUAL)
Registered Start Date2018-11-19
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI